

**VIVALIS ANNOUNCES A NEW EB66® TECHNOLOGY RESEARCH LICENSE WITH
KYOTO BIKEN LABORATORIES**

Nantes & Lyon (France) – November 6th, 2012 – VIVALIS (NYSE Euronext: VLS) announced today that it has signed new research license with Kyoto Biken Laboratories, Inc., (“Kyoto Biken”), based in Japan, for a cell line derived from Vivalis’ proprietary EB66® technology platform for the production of animal health vaccines.

Kyoto Biken currently maintains a commercial license agreement to the EB66® cell line for the production of poultry vaccines.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, “This new licensing agreement expands the utility of the EB66® platform, which was used to develop the EB66® cell line. Today, over 30 agreements have been signed for the use of the EB66® technology platform for the production of both human and animal health biologics, including vaccines and recombinant proteins, including ten license and collaboration agreements signed since January 2012. Leveraging our assets in cell line development is a strategic initiative of Vivalis and this agreement furthers our mission to develop products demanded by our customers, world-wide.”

Financial terms of the agreement were not disclosed.

Next Financial Press Release

**January 15th, 2013, after NYSE Euronext market closing:
2013 Financial calendar**

About VIVALIS (www.vivalis.com)

Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis’ expertise and intellectual property are leveraged in two main areas:

1. EB66® Cell Line

Vivalis offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, including monoclonal antibodies. Clinical trials of EB66® produced vaccines are currently on-going in the USA and Japan and in 2012 a vaccine produced in EB66® cells received market approval in Japan for use in animal health. Through these programs, Vivalis receives an upfront payment, clinical stage milestone payments along with royalties on licensees’ net sales.

2. VIVA|Screen™ Human Antibody Discovery Platform

Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the

funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the use of the platform.

Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.

VIVALIS

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext’s SBF 250, CAC Small 90 and Next Biotech indexes



This document contains forward-looking statements and comments on the company’s objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company’s Document de Référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

VIVALIS

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0) 1 44 71 94 93

Email: vivalis@newcap.fr